Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Oncopeptides AB's gross profit for the
three
months ended in Mar. 2026 was kr25.06 Mil. Oncopeptides AB's gross profit for the trailing twelve months (TTM) ended in Mar. 2026 was kr80.49 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Oncopeptides AB's gross profit for the
three
months ended in Mar. 2026 was kr25.06 Mil. Oncopeptides AB's Revenue for the
three
months ended in Mar. 2026 was kr25.38 Mil. Therefore, Oncopeptides AB's Gross Margin % for the quarter that ended in Mar. 2026 was 98.74%.
Oncopeptides AB had a gross margin of 98.74% for the quarter that ended in Mar. 2026 => Durable competitive advantage
During the past 12 years, the highestGross Margin % of Oncopeptides AB was 103.06%. The lowest was 55.09%. And the median was 96.55%.
Oncopeptides AB (CHIX:ONCOs) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Oncopeptides AB had a gross margin of 98.74% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Oncopeptides AB Gross Profit Related Terms
Oncopeptides AB Gross Profit Historical Data
* Premium members only.
The historical data trend for Oncopeptides AB's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:ONCOS vs VRTX, REGN, RVMD: Gross Profit Comparison
For the Biotechnology subindustry, Oncopeptides AB's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncopeptides AB Gross Profit vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oncopeptides AB's Gross Profit distribution charts can be found below:
* The bar in red indicates where Oncopeptides AB's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr80.49 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Oncopeptides AB (CHIX:ONCOS) has a Gross Profit of kr80.49 Mil as of Mar. 2026. Gross Profit equals net sales less total cost of goods sold. View historical data on Oncopeptides AB and its competitors.
Is Oncopeptides AB's Gross Profit too high?
Oncopeptides AB's current Gross Profit is kr80.49 Mil. Overall, Oncopeptides AB has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Oncopeptides AB's Gross Profit compare to VRTX and REGN?
Oncopeptides AB's Gross Profit of kr80.49 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Biotechnology company?
A good Gross Profit depends on the Biotechnology industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Oncopeptides AB and its competitors. Oncopeptides AB's current Gross Profit is kr80.49 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncopeptides AB stock overvalued right now?
Based on GuruFocus' analysis, Oncopeptides AB (CHIX:ONCOS) is currently considered Possible Value Trap. The stock's GF Value™ is kr5.80, compared to a current price of kr1.72 — trading 70.3% below its estimated fair value. The current Gross Profit is kr80.49 Mil. Oncopeptides AB's overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Oncopeptides AB (CHIX:ONCOS), the current Gross Profit is kr80.49 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncopeptides AB (CHIX:ONCOS) Overvalued in 2026?
Based on GuruFocus' analysis, Oncopeptides AB stock appears to be undervalued.
The current stock price of kr1.72 is trading 70.3% below its estimated GF Value™ of kr5.80.
GuruFocus considers Oncopeptides AB to be Possible Value Trap.
Key valuation signals for CHIX:ONCOS:
Gross Profit: kr80.49 Mil
GF Value™: kr5.80 vs. price of kr1.72 (70.3% below fair value)
No single metric tells the full story. See the CHIX:ONCOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncopeptides AB is a Swedish biotech company focusing on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company uses its proprietary Peptide Drug Conjugate platform to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It is a science-driven biotech company developing targeted therapies for hard-to-treat cancers, combining cutting-edge research, entrepreneurial spirit, and a deep commitment to improving patients' lives. Its flagship drug is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East, Africa, and elsewhere. The company generates maximum revenue from Germany.
46GF Score
Get the complete analysis for CHIX:ONCOS
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:ONCOS has been successfully added to your 
